New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review

Table 1

Kinase inhibitor activities of target therapies on thyroid cancer [16–18].

Drug	Inhibitory concentration 50 [IC50] (nmol/L)
	VEGFR-1	VEGFR-2	VEGFR-3	RET	BRAF^V600E	PDGFR-β	Kit	Others
Sorafenib	26	90	20	49	25	57	68
Axitinib	1.2	0.25	0.29			2	1.7
Motesanib	2	3	6	59		84	8
Sunitinib	2	9	17	41		39	1–10
Pazopanib	10	30	47			84	74
Lenvatinib (E7080)	22	4	5	35		39		FGFR1 (46)
Cabozantinib (XL-184)		0.035		4				cMET (1.8)
Vandetanib	1600	40	110	130				EGFR (500)
Gefitinib		>10000		3700				EGFR (33)
Selumetinib								MEK1 (14)
Dabrafenib					0.8